TG THERAPEUTICS, INC. (TGTX) Form 8-K — Aug 3, 2026
TG Therapeutics reported second quarter 2026 total global revenue of approximately $240 million, driven by BRIUMVI U.S. net product revenue of approximately $228 million, which represents a 64% increase over the same period last year. Based on the strong commercial performance, the company raised its full year 2026 total global revenue target to approximately $950 million and increased its BRIUMVI U.S. net product revenue target to $890-$905 million.
Key figures
- Eps
- $0.05
- Revenue
- $240.3 million
- Guidance
- $950 million
- Net Income
- $7.8 million
- Cash Position
- $612.3 million
- Rd Expenses
- $95.3 million
- Sga Expenses
- $82.1 million
- Revenue Growth
- 64%
- Briumvi Q2 Revenue
- $227.7 million
- Full Year Briumvi Guidance
- $890 - $905 million
Price after filing
1 day: 0.0%7 days: -8.2%30 days: +4.8%
Close on the filing date to close N calendar days later (from $53.53). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.